Servier's sevasemten misses primary endpoint in pivotal Phase 3 Becker muscular dystrophy trial

What happened: ServierDealroom has a profile for this one. Try Dealroom → announced on 3 November 2026 that sevasemten, its investigational drug for Becker muscular dystrophy (BMD), failed to meet the primary endpoint in the pivotal Phase 3 GRAND CANYON study. BMD is a genetic condition in which a shortage of dystrophin, a protein that keeps muscle cells intact, causes progressive muscle weakness. The 18-month, global, placebo-controlled trial showed no statistically significant benefit on the North Star Ambulatory Assessment (NSAA), a scale that measures how well patients can walk, climb and move. Secondary endpoints were also missed, though the drug maintained a favourable safety and tolerability profile.

Why it matters: The result contrasts with earlier findings from the Phase 2 CANYON study, which had supported advancing sevasemten — a drug designed to block an enzyme that damages weakened muscle — into a registration programme. Servier said it is conducting a comprehensive analysis of the dataset to explain the discrepancy. The miss is a setback for people with BMD, a milder form of Duchenne muscular dystrophy, who currently have no approved disease-modifying treatment.

Read more: Servier, 3 November 2026